Not for any specific indication
And the results of that trial were published last August (2017): Title: Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial Authors: Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T Journal: Lancet 2017 Aug 3
Regular follow-ups are necessary to monitor weight loss progress, adjust dosages as needed, manage side effects, and catch any early warning signs of complications such as gallbladder issues or pancreatitis
Specifically, GLP1 is secreted by L cells and GIP by K cells in response to the presence of glucose in the gut lumen
Permanent effects are rare and usually linked to misuse or unregulated products
It is also not recommended for use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as semaglutide may increase the risk of these conditions
